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Background: To evaluate the in vivo response by detecting the anti-angiogenic and invasion-inhibiting effects
of a triple-combination-therapy in an experimental-small-animal-squamous-cell-carcinoma-model using the
“flash-replenishment” (FR) method to assess tissue hemodynamics via contrast-enhanced-ultrasound (CEUS).
Methods: Human hypopharynx-carcinoma-cells were subcutaneously injected into the left flank of
22-female-athymic-nude-rats. After seven days of subcutaneous tumor growth, FR-measurements were performed on
each rat. Treatment-group and control-group were treated every day for a period of one week, with the
treatment-group receiving solvents containing a triple therapy of Upamostat®, Celecoxib® and Ilomastat® and the
control-group solvents only. On day seven, follow-up measurements were performed using the same measurement
protocol to assess the effects of the triple therapy. VueBox® was used to quantify the kinetic parameters and
additional immunohistochemistry analyses were performed for comparison with and validation of the CEUS results
against established methods (Proliferation/Ki-67, vascularization/CD31, apoptosis/caspase3).
Results: Compared to the control-group, the treatment-group that received the triple-therapy resulted in a reduction
of tumor growth by 48.6% in size. Likewise, the immunohistochemistry results showed significant decreases in tumor
proliferation and vascularization in the treatment-group in comparison to the control-group of 26%(p≤0.05) and
32.2%(p≤0.05) respectively. Correspondingly, between the baseline and follow-up measurements, the therapy-group
was associated with a significant(p ≤ 0.01) decrease in the relative-Blood-Volume(rBV) in both the whole tumor(wt) and
hypervascular tumor(ht) areas (p≤0.01), while the control-group was associated with a significant (p≤0.01) increase of
the rBV in the wt area and a non-significant increase (p≤0.16) in the ht area. The mean-transit-time (mTT) of the wt and
the ht areas showed a significant increase (p≤0.01) in the follow-up measurements in the therapy group.
Conclusion: The triple-therapy is feasible and effective in reducing both tumor growth and vascularization. In
particular, compared with the placebo-group, the triple-therapy-group resulted in a reduction in tumor growth
of 48.6% in size when assessed by CEUS and a significant reduction in the number of vessels in the tumor of
32% as assessed by immunohistochemistry. As the immunohistochemistry supports the CEUS findings, CEUS
using the “flash replenishment”(FR) method appears to provide a useful assessment of the anti-angiogenic and
invasion-inhibiting effects of a triple combination therapy.
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Occult tumor cells that can lead to loco-regional recur-
rence and distant metastases are the main reason for the
poor prognosis of patients suffering from squamous cell
carcinoma of the head and neck [1]. Tumor cells utilize
a complex set of molecular mechanisms in order to
metastasize [2]. Invasive migration through and remod-
eling of surrounding tissue is achieved upon degradation
of the extracellular matrix (ECM). In this respect, the
urokinase-type plasminogen-activator system (uPA) and
matrix metalloproteases (MMP) are of major import-
ance. The activity of MMPs and the uPA fosters cell
migration, angiogenesis and metastasis [3,4]. Tumors
greater than 1.5 mm3 in size require intimate contact
with blood vessels or otherwise become necrotic [5].
Neoangiogenesis, i.e. the formation of new blood vessels,
is provided via the production of chemoattractans,
which redirect endothelial cells into the tumor tissue to
enable tumor progression. In turn, de novo formed ves-
sels enhance tumor invasion and metastasis through the
production of MMP 2 and 9 and uPA, which further
degrade ECM. The in vivo anti-metastatic and anti-
proliferative activity of the synthetic uPA inhibitor
WX-UK1 has been demonstrated in various animal
tumor models [6], especially the suppression of rat
breast cancer metastasis and reduction of primary
tumour growth by the small synthetic urokinase in-
hibitor WX-UK1 [7].
WX-UK1 is the active metabolite of the oral prodrug
Upamostat® administered as a component of the triple
therapy in this study. Inhibition of MMPs has pro-
vided a significant increase in the survival rate in clin-
ical trials, according to the frequent overexpression of
MMPs in malignant tumors and the correlation with a
highly aggressive phenotype and poor prognosis
[8-10]. Combinatorial inhibition of MMPs and the
plasminogen activator system using siRNA approaches
likewise revealed effectiveness with a 60% and 90%
down-regulation of invasion and angiogenesis, respect-
ively [11,12]. Non-steroidal anti-inflammatory drugs are
a group of pharmaceutical agents with anti-angiogenic
properties. In vitro studies suggested a potential of
cyclooxigenase-2 (COX-2) inhibitors to reduce the
growth of colon, head and neck, and skin tumors and to
block angiogenesis [13,14].
Former studies using the serine protease inhibitor
WX-UK1, in which the effects on the capacity of tumor
cell spheroids to invaginate and invade fibroblast spher-
oids were tested, present a reduction of tumor cell
invasion of 50% using WX-UK1 alone [15]. Previous
experience disclosed that only multimodal therapy strat-
egies properly take into account the plethora of mecha-
nisms underlying tumor progression and are hence
indispensable. Thus, a promising concept is a combinationof inhibitors that address different aspects of tumor pro-
gression and metastasis formation [16,17].
A previous in vitro study, which combined the serine
protease inhibitor WX-UK1, the MMP inhibitor
Ilomastat® and the selective COX-2 inhibitor Celecoxib®,
demonstrated an inhibition of tumor cell invasion in a
spheroid model of 80% and inhibition of angiogenesis by
40% in a HUVEC sprouting model [18]. The degree of
neoangiogenesis is crucial for tumor growth and the
propensity for forming metastasis. A number of molecu-
lar drugs promise to be effective at inhibiting tumor
angiogenesis.
Established methods of monitoring therapy, such as
assessing the size and growth behavior of a tumor during
therapy (using RECIST criteria) or progression-free sur-
vival of patients, are not sensitive enough and not suffi-
ciently specific to detect the subtle effects of these new
molecular therapeutics in the early stages of therapy.
Multiple preclinical studies, with varying degrees of suc-
cess, have attempted to display different functional pa-
rameters of tumor microcirculation and for therapy
monitoring of an anti-angiogenic treatment [19-23], e.g. by
means of contrast-enhanced ultrasound imaging.
One major advantage of CEUS is its non-invasive na-
ture allowing for the depiction of various organs with
high spatial and temporal resolution without the use of
ionizing radiation. Ultrasound contrast agents (e.g.
Sonovue®) contain a gas that is exhaled via the lungs
such that elimination from the body is usually ensured
within a few minutes. In contrast to iodine and gadolin-
ium, these ultrasound contrast agents are not eliminated
via renal excretion, so they are not contra-indicated for
patients with impaired renal function.
Conventional, indicator-based methods for the assess-
ment of tissue hemodynamics rely on the administration
of a bolus of contrast agent (CA) and the subsequent
monitoring of the temporal distribution of the contrast
agent in the tissue with an appropriate imaging modality
and are often referred to as “bolus tracking” measure-
ments. In addition to these bolus-tracking techniques,
CEUS offers the unique method of “flash-replenishment”
measurements. Here, imaging takes place not during the
injection of CA, but afterwards, when a nearly constant
concentration of CA is achieved. Dynamic information
is obtained by disrupting the micro bubbles in the im-
aging plane with a pulse with high mechanical index,
thus creating a “negative” bolus. Subsequently, micro
bubbles are carried into the imaging plane by blood flow
in the tissue, thus allowing the derivation of various
hemodynamic tissue parameters from the dynamics of
the replenishment.
The purpose of this study was to transfer the promis-
ing in vitro triplet therapy into an in vivo model using
immunohistochemistry for evaluation of the response as
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sponse by detecting the anti-angiogenic and invasion-
inhibiting effects of the serine protease inhibitor
Upamostat®, the MMP inhibitor Ilomastat® and the
selective COX-2 inhibitor Celecoxib® using the relatively
new “flash replenishment” (FR) method for the assessment
of tissue hemodynamics coupled with contrast-enhanced
ultrasound (CEUS) in an experimental small-animal squa-
mous cell carcinoma model.
Methods
Animal model and experimental protocol
The study was performed with the approval of the
Institutional Committee for Animal Research in ac-
cordance with the guidelines of the National Institute
of Health for the care and use of laboratory animals.
All animal experiments were approved by the Bavarian
state government (Application number: 55.2-1-54-2531-
162-10).
6 × 106 human hypopharynx carcinoma cells were
injected subcutaneously into the left abdominal flank of
22 female athymic nude rats (Charles River®, Sulzfeld,
Germany/7-8 weeks old/180-220 g body weight). The
animals were inspected daily to assess general appear-
ance and tumor growth. When tumors reached a size
of ~1.2 cm in the largest probe based on caliper mea-
surements in two dimensions (median seven days of
subcutaneous tumor growth/SD two days), CEUS mea-
surements were performed using a high-end ultrasound
system (Siemens Sequoia 512®/ Acuson, Mountain View,
Germany). For examinations, animals were anesthetized
with intraperitoneal injections of Ketamine® (100 mg/kg
bodyweight, Ketavet®, Pfizer Inc. ©, New York, NY) and
Xylazine® (10 mg/kg bodyweight, Rompun® 2%, Bayer,
Leverkusen, Germany). A 22-gauge butterfly catheter
(B. Braun AG®, Melsungen, Germany) was inserted
into a tail vein for the manual injection of contrast
media. After tumor tissue was contrasted homoge-
neously, all microbubbles in the imaging plane were
eliminated with a high-energy pulse. Subsequent replen-
ishment of the microbubbles in the sonic plane was ob-
served and recorded. To prevent motion artifacts, the
transducer was not held by hand but was fixed in a dedi-
cated device. The transducer position of the baseline scan
was recorded photographically to allow reproduction of
the same conditions for the follow-up measurements.
Both the treatment group and the control group
received a daily application of solvents for a period
of one week with the control group receiving sol-
vents only while the solvents of the treatment group
also included the triple therapy of Upamostat®, Celecoxib®
and Ilomastat®. After six days of treatment, follow-up mea-
surements were performed the next day using the identical
measurement protocol to assess the effect of the tripletherapy. Video sequences were exported and analyzed with
VueBox® (Bracco Suisse®, Geneve, Switzerland) as described
previously [20]. In addition, immunohistochemistry
analyses (Proliferation/Ki-67, vascularization/CD31,
apoptosis/caspase3) were performed to validate the CEUS
measurements.
Contrast-enhanced ultrasound (CEUS)
Technical developments over the past decade have fo-
cused on different microbubble consistencies as well as
effective methods of detecting their non-linear signals.
The low mechanical index allows the production of real-
time gray-scale images. Contrast-specific techniques use
a low applied acoustic pressure to produce images based
on nonlinear acoustic interaction between the ultra-
sound system and stabilized microbubbles. These
microbubbles oscillate and resonate, giving continuous
contrast enhancement to gray-scale images. SonoVue®
(Bracco®, Milan, Italy) is a second-generation contrast
agent consisting of stabilized microbubbles of sulfur
hexafluoride gas, allowing for direct and easy removal
via the respiratory system. While low in solubility, it is
innocuous, isotonic with human plasma and devoid of
antigenic potential since it contains no proteinaceous
component. The required dosage for a single injection
was 0.3 ml followed by 0.3 ml of saline to improve
the detection of contrast enhancement in the tumor
tissue.
Triple therapy
Upamostat® (Wilex®, Munich, Germany) at a concentra-
tion of 0.03 mg/kg in 0.1 ml stock (9.6 ml Aqua dest
and 0.4 ml Ethanol), Ilomastat® (50 mg/kg in 0.1 ml
Ethanol, US Biological, Massachusetts, U.S.A), and
Celecoxib® (25 mg/kg in 0.1 ml Ethanol, Pfizer, Berlin,
Germany) were administered to the animals via gavage
each day. The control group received the same quantity
of solvents without any drugs. In both groups, 0.2 ml
Ulcogant (Merck®, Darmstadt, Germany) was then ad-
ministered following the solvent treatment to block acid
in the stomach.
Data analysis with VueBox
Consensus reading data evaluation was performed in a
blinded manner by an experienced radiologist (five years
in-depth experience) and a physicist (main focus perfu-
sion quantification, 6 years experience) using the digit-
ally stored video sequence data sets for the analysis of
the contrast-enhanced ultrasound examinations. The
regions of interests (ROIs) were always drawn to the en-
tire tumor and to a hypervascular tumor site because
the tumor changed throughout treatment. Follow-up in-
vestigation was performed promptly to ensure that
hypervascular areas were compared in identical tumor
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from the flash-replenishment measurement, a lognormal
model [24-27] was fitted to the time-intensity curves of
the previously defined regions, yielding estimates for the
relative blood volume (rBVFR), wash-in rate (WiRFR),
mean transit time (mTTFR) and relative blood flow
(rBFFR) as the ratio of rBVFR and mTTFR.
Immunohistochemistry
Consecutive cryosections (4 μm) of each tumor were
fixed in acetone (10 min, RT) and incubated in H2O2
(10 min, RT, 0.03%) to block endogenous peroxidase ac-
tivity. Subsequently, slides were incubated with either
mouse anti-rat CD31 (1:100,2 h, Becton Dickinson®,
Heidelberg, Germany), rabbit anti-human Caspase-3
(1:50; 2 h, Cell Signaling, Boston, MA, USA), mouse
anti-human EpCAM VU1D9 (1:2000; 1 h, Cell Signaling,
Boston, MA, USA) or mouse anti-human Ki67 (1:800;1 h,
Dako®, Hamburg, Germany). Thereafter, sequential incu-
bations with biotinylated anti-mouse, rat-adsorbed (for
CD31, EpCAM and Ki67), anti-rabbit secondary antibody
(for Caspase 3), and peroxidase-labelled avidin-biotin-
peroxidase complex were conducted (Vector Lab. Inc.®,
Burlingame, CA, USA). Amino-ethyl-carbazole (AEC) per-
oxidase substrate was used for the detection of antigen/
antibody complexes indicated by red-brown staining.
Counter-staining was achieved with hematoxylin (blue).
Negative controls were conducted simultaneously using
respective mouse/ rabbit isotype-control antibody (Cell
Signaling). Finally, sections were mounted in Kaiser’s gly-
cerol gelatin for subsequent analysis.Figure 1 In the placebo group, the tumors grew aggressively in average c
(grey graph). The tumors size increased 101.4%. In the group that received
tumor was 1.25 cm2 at the beginning of the therapy and grew up to 1.91
the increase in tumor size of 48.6% (p≤ 0.05).Evaluation of immunostaining
Proliferation and apoptosis rate were measured as the
percentage of Ki67 and caspase-3 positive cells amongst
all tumor cells, respectively. Furthermore, vascularization
was measured as the amount of CD31-positive vessels in
the tumor. The results given are relative to control-treated
rats, which we have evaluated in comparable groups under
the same circumstances.
Laser scanning fluorescence microscopy
The presence of Ki67-positive tumor cells and CD31-
positive vessels in rat stroma tissue was analyzed using a
fluorescence laser scanning system (TCS-SP2 scanning
system and DM IRB inverted microscope, Leica®, Solms,
Germany). Ki67 and CD31 staining were performed with
specific antibodies as described above. Dye-coupled
Alexa antibodies (Alexa-488 for Ki67 in green and
Alexa-647 for CD31 in red; Molecular Probes, Eugene,
USA) were used as secondary antibodies. Subsequently,
Hoechst 33342 was used for labeling of nuclear DNA
(Sigma®, Taufkirchen, Germany). Leica Confocal Software
Lite (Leica®, Solms, Germany) was used for evaluation ac-
cording to the manufacturer’s instructions.
Statistical analysis
Continuous variables are presented as the mean and
standard deviation or absolute and relative frequencies if
appropriate. Given the parametric distribution, a paired
Student’s T-test was employed to compare measure-
ments obtained at baseline and follow-up, an unpaired
Studient’s T-test was use for comparisons of continuousrosssection from 1.36 cm2 to 2.74 cm2 on the last day of treatment
the triple therapy, the tumor increase in size by 52.8%. The average
cm2 at the end (black graph). The therapy resulted in a reduction of
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Also, median percentage changes between baseline
and follow-up of CEUS parameters as well as for the
immunohistochemical data of the control and treat-
ment groups were calculated. Analyses were carried
out using SPSS (IBM SPSS Statistics, USA, Version 20).
P values of < 0.05 were considered to indicate statistical
significance.
Results
CEUS measurements were successfully performed with-
out any technical difficulties in all 22 rats. Two animals
died of anesthetic complications before the follow-upFigure 2 Therapy group : dark gray/Controll group : light gray. Subsequen
of the relative Blood Volume (rBV) between the baseline and follow-up me
tumor (ht) areas (b) (p ≤ 0.01). The mean Transit Time (mTT) of the wt (c) a
follow-up measurements. In the control group, we observed a significan
measurements of the wt and a minor increase (p ≤ 0.16) of the ht areas
changes in the follow-up measurements.measurements. The mean examination time for the CEUS
measurements was 6.9 minutes, excluding animal prepar-
ation. After seven days of median subcutaneous tumor
growth (SD two days), the mean tumor volume based on
two-dimensional caliper measurements was ~130 mm2.
No side effects due to administration of the contrast
medium were observed.
Tumor diameter: (therapy vs. control)
In the placebo group, the tumors grew aggressively with
an average growth in cross-section from 1.36 cm2 to
2.74 cm2 on the last day of “treatment”. Tumor size in-
creased by 101.4% on average. In the group that receivedtly, in the therapy group we observed a significant (p≤ 0.01) decrease
asurements of the whole tumor (wt) (a) and of the hypervascular
nd the ht (d) areas showed significant increase (p ≤ 0.003/0.001) in the
t (p ≤ 0.01) increase of the rBV between the baseline and follow-up
. The mTT of the wt and the ht areas showed no significant
Figure 3 The contrast-enhanced ultrasound image shows a significant reduction of the vascularization between the baseline (a) and follow-up
(c) scan. Although the tumor grew in size during treatment, must of the tumor is necrotic. The blood volume parameter maps show a
corresponding decrease of the relative Blood Volume (rBV) within the remaining hypervascular tumor betwenn the baseline (b) and
follow-up (d) scan.
Table 1 Absolute values of the whole tumor and the hypervascular area at baseline and follow-up for the therapy and
control group (parameters: relative Blood Volume, mean Transit Time (s), Perfusion Index (rBV/mTT), Wash-in Rate)
Whole tumor Hypervascular area
Baseline Follow-up P Baseline Follow-up p
Mean SD Mean SD Mean SD Mean SD
Therapy: relative Blood Volume 337.3 273 164.3 193.7 0.01 595.4 448.8 190.3 57.4 0.01
Control: relative Blood Volume 131.6 72 529.9 237.2 0.01 320.8 183.5 414.9 51.1 0.16
Therapy: mean Transit Time (s) 4.2 2.0 8.3 5.1 0.01 4.8 2.3 13.2 6.5 0.01
Control: mean Transit Time (s) 6.8 5.2 4.5 1.9 0.18 4.7 2.6 6.6 5.6 0.34
Therapy: Perfusion Index (rBV/mTT) 102.6 96 27.4 39.3 0.01 177.2 197.0 32.0 50.9 0.01
Control: Perfusion Index (rBV/mTT) 30.2 25 123.9 63.7 0.01 91.2 57.4 121.8 95.2 0.38
Therapy: Wash-in Rate 37.5 33 11.7 8.3 0.01 102.8 76.8 25.5 14.3 0.01
Control: Wash-in Rate 21.6 16 27.9 25.8 0.6 63.6 39.8 154.3 84.4 0.01
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Figure 4 Immunohistochemistry revealed a significant decrease of
the proliferation (a) and number of vessels (b) in the tumor and a
significant increase of the apoptosis rate (c) in the treatment group
compared with the placebo group.
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average with the average tumor 1.25 cm2 in cross-
section at the beginning of the therapy growing to
1.91 cm2 at the end. The therapy resulted in a reduction
of the increase in tumor size of 48.6%. This represents a
statistically significant and strong reduction of tumor
growth upon application of triple medication (p ≤ 0.05).
In addition, 14 days after tumor implantation and after
six days of therapy, the average tumor mass was 1.5 g
in the treatment group and 2.1 g in the placebo group
(p = 0.3) (see Figure 1).
CEUS quantification using Vuebox
In the control group, we observed a significant (p ≤ 0.01)
increase of the relative blood volume (rBV) between the
baseline and follow-up measurements of the whole
tumor from 131.6 (SD 72.1) to 529.9 (SD 237.2) and a
non-significant increase (p ≤ 0.16) of the hypervascular
tumor areas from 320 (SD 183.5) to 414.9 (SD 51.1). In
contrast, we observed a significant (p ≤ 0.01) decrease of
the rBV between the baseline and follow-up measure-
ments of the whole tumor from 338.3 (SD 272.8) to
164.3 (SD 193.7) and of the hypervascular tumor areas
from 595.4 (SD 448.8) to 190.3 (SD 57.4) (p ≤ 0.01) in
the therapy group. Please see also Figures 2 and 3.
The mean Transit Time (mTT) of the whole tumor
and the hypervascular tumor areas showed no significant
changes (p ≤ 0.182/0.338) in the follow-up measure-
ments (baseline: 6.8; SD 5.2/follow-up: 4.5; SD 1.9//base-
line: 4.7; SD 2.6/follow-up: 6.6; SD 6.6) in the control
group. In contrast, in the therapy group the mTT of the
whole tumor and the hypervascular tumor areas showed
a significant increase (p ≤ 0.01/0.01) in the follow-up
measurements (baseline: 4.2; SD 2/follow-up: 8.3; SD
5.1//baseline: 4.8; SD 2.3/follow-up: 13.2; SD 6.5). Please
see also Figures 2 and 3.
In the control group a significant increase (p ≤ 0.01) of
the Perfusion Index (rBV/mTT) was observed for the
whole tumor (baseline: 30.2; SD 24.7/follow-up: 123.9;
SD 63.7), while the hypervascular tumor areas (baseline:
91.2; SD 57.4/follow-up: 121.8; SD 95.2) revealed only
a minor increase (p ≤ 0.376). A significant decrease
(p ≤ 0.01/0.01) of the Perfusion Index was observed for
the whole tumor (baseline: 102.6; SD 96.1/follow-up:
27.4; SD 39.3) and the hypervascular tumor areas
(baseline: 177.2; SD 197/follow-up: 32; SD 50.9) in the
therapy group.
The Wash-in Rate (WiR) displayed a minor increase of
the whole tumor (p ≤ 0.596) and a significant (p ≤ 0.01) in-
crease of the small hypervascular tumor areas (baseline:
21.6; SD 16/follow-up: 27.9; SD 25.8//baseline: 63.6; SD
39.8/follow-up: 154.3; SD 84.4) in the control group. In
contrast, the WiR also displayed a significant decrease of
the whole tumor (p ≤ 0.01) and the small hypervasculartumor areas (baseline: 37.5; SD 32.6/follow-up: 11.7; SD
8.3//baseline: 102.8; SD 76.8/follow-up: 25.5; SD 14.3) in
the therapy group.
No significant differences were observed within each
group (p > 0.05) or between the baseline measurements
of the control and therapy groups. Please see also
Table 1.
Immunohistochemistry
Proliferation of the tumors treated with the triple ther-
apy was 26% less in comparison to the placebo group
(p ≤ 0.05). The apoptosis rate was 1.8 times higher in the
therapy group compared to the placebo group (p ≤ 0.01).
Paprottka et al. BMC Cancer  (2015) 15:373 Page 8 of 11The number of vessels in the tumor was reduced by
32% in the triple therapy group compared with the pla-
cebo group (p ≤ 0.05) (see Figures 4, 5 and 6).
In particular, the proliferation rate was determined as
the percentage of Ki67 positive cells among all cells in
the tumor. Likewise, the apoptosis rate was measured as
the percentage of Caspase3-positive cells. Furthermore,
the vascularization was measured as the number of
CD31 positive vessels in the appropriate tissue. All
results are given relative to control-treated rats.
Discussion
Previous reports disclosed that multimodal therapy strat-
egies are more suitable to efficiently address the plethoraFigure 5 Immunohistochemistry revealed a significant decrease of the pro
group (b). The number of vessels (red) in the therapy group (c) decreased
significant increase of the apoptosis rate (red) in the treatment group (e) cof mechanisms underlying tumor progression than single
therapeutics. Thus, the combination of inhibitors that
target different aspects of tumor progression and metas-
tasis formation is a promising concept [16,17].
We have previously demonstrated in vitro the efficacy
of a combination of the serine protease inhibitor WX-
UK1, the MMP inhibitor Ilomastat® and the selective
COX-2 inhibitor Celecoxib® [18]. Triple medication re-
duced tumor cell invasion by 80% and neoangiogenic
sprouting of HUVECs by 40%. In the present study, the
potential of triple medication was assessed in a small-
animal model of cancer. Head and neck carcinoma cells
were xenotransplanted into athymic nude rats and
tumor size, proliferation, and perfusion were analysedliferation (red) in the therapy group (a) in comparison to the placebo
in comparison to the untreated group (d) and we observed a
ompared with the placebo group (f).
a b
Figure 6 Figure 6 shows the expression of Ki67-positive (green) tumor cells and CD31-positive (red) vessels in the tissue analyzed using a fluorescence
laser scanning system. Immunohistochemistry revealed a significant decrease of the proliferation and the number of vessels in the therapy group (a) in
comparison to the placebo group (b).
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chemistry. In the therapy group the proliferation was
reduced by 26% (p ≤ 0.05). The apoptosis rate of the tu-
mors treated with the triple therapy showed a significant
increase of 1.8 times in comparison to the control group
(p ≤ 0.01). As expected due to the pharmacological
mechanism of action, the number of vessels in the
tumor showed a significant reduction by 32% in the
triple therapy group compared with the placebo group
(p ≤ 0.05). The therapy resulted in an increase of apo-
ptose and a decrease of prolifertation and angiogenesisa,
indicating a reduction in tumor invasion, which was
measured as a reduction in tumor growth. Thus, these
results demonstrate the efficacy of triple medication
in vivo and support the further transfer of knowledge to
pre-clinical and clinical settings. Young et al. showed in
their study with the cell line YD-10B (squamous cancer
of the tongue) a dose-dependent inhibition of tumor
growth and proliferation up to 60% with Celecoxib®
alone [24]. An in vivo study using Celecoxib® in a mouse
model in 2006 also demonstrated an increase of caspase
three and nine and an increase of apoptoserate in the
tumor cells, which resulted in a decrease in tumor
growth [25].
Hawinkels et al. were also able to show a reduction of
neoangiogenesis using the MMP inhibitor GM6001 and
Marimastat using colorectal tumor cells in vitro [26]. A
more direct and detailed comparison of our results to
other studies was not feasible, because, to the best of
our knowledge, there are no other studies that also in-
clude the described triplet therapy in an experimental
small-animal squamous cell carcinoma model.
Since a histological follow-up of an anti-angiogenic
therapy is clinically infeasible, as it is not appropriate forthe patients to undergo repetitive biopsies within short
time spans, we choose the CEUS method to assess ef-
fects on tissue hemodynamics as a surrogate for anti-
angiogenic and invasion-inhibiting effects of the triple
combination therapy.
We decided to use CEUS imaging because it is one of
the most promising tools for imaging tumor angiogen-
esis and monitoring therapeutic effects of anti-vascular
tumor therapy due to its lack of ionizing radiation,
non-invasiveness, wide clinical availability and cost-
effectiveness. The bolus tracking technique is a well-
known and established technique that can be used in
a wide range of modalities including CEUS, CT and
MRI. However, due to the well-known disadvantages
of this technique, e.g. the need to acquire an arterial
input function in a blood vessel, we chose the flash
replenishment method for the assessment of the tissue
hemodynamics for our study. The flash replenishment
method is specifically tailored to CEUS, and the results
are independent of the injection speed or cycle time.
Additionally, Paprottka and Ingrisch could demonstrate
that although the lack of absolute, quantitative parame-
ters hinders a direct comparison of both modalities, FR
and BT are both suitable for relative comparison, e.g. be-
tween baseline and follow-up examinations [20].
Previous preclinical studies have shown that grey-scale
ultrasound measurements of micro bubble contrast
agent flow can be used to investigate tumor angiogenesis
[19-23] to estimate the effects of antiangiogenic tumor
therapy [19,27-36]. However, a direct comparison of our
results to other studies was not possible because, to the
best of our knowledge, there are no other studies that
also include the described triplet therapy in an experi-
mental small-animal squamous cell carcinoma model.
Paprottka et al. BMC Cancer  (2015) 15:373 Page 10 of 11As confirmed by the immunohistochemical procedure,
the number of vessels in the tumor showed a significant
reduction by 32% in the triple therapy group compared
with the placebo group (p ≤ 0.05). Correspondingly,
CEUS indicated a significant (p ≤ 0.01) decrease of the
relative blood volume (rBV) and a significant increase of
the mean transit time (mTT) in the therapy group be-
tween the baseline and follow-up measurements in both
the whole tumor and the hypervascular tumor areas.
Oppositely, the control group showed a significant
(p ≤ 0.01) increase of the rBV in the whole tumor and a
minor increase (p ≤ 0.16) of the rBV in the hypervascular
tumor areas and no significant changes (p ≤ 0.182/0.338) of
the mTT in either the whole tumor or the hypervascular
tumor areas.
Our results indicate that quantitative detection of the
tumor response during antiangiogenic treatment should
be possible in the near future even in small tumors, i.e.
tumors with a size of ~130 mm2 or greater. Although
the well-known limitations of ultrasound such as obesity,
meteorism and noncompliance are also present for
CEUS, due to the superficial position of the tumor and
the intraperitoneal anesthetized injection, these limita-
tions were of no consequence in our study. The study is,
however, limited in direct applicability by the fact that
our measurements were made in an experimental animal
model under optimized experimental conditions such
that the results may not be 100% transferable to clinical
practice.
Conclusion
The triple therapy is feasible and leads to a significant
reduction by 32% of the number of vessels in the tumor
in the triple therapy group compared with the placebo
group, as proven by immunohistochemistry and a reduc-
tion of tumor growth of 48.6%. The anti-angiogenic and
invasion-inhibiting effects of a triple combination ther-
apy can be assessed non-invasively with CEUS using the
“flash replenishment” (FR) method.
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